Citigroup’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-10,736
| Closed | -$24.5K | – | 5838 |
|
|
2024
Q2 | $24.5K | Sell |
10,736
-118,330
| -92% | -$452K | ﹤0.01% | 4938 |
|
|
2024
Q1 | $558K | Buy |
129,066
+43,117
| +50% | +$150K | ﹤0.01% | 3491 |
|
|
2023
Q4 | $262K | Buy |
85,949
+85,306
| +13,267% | +$160K | ﹤0.01% | 3813 |
|
|
2023
Q3 | $926 | Sell |
643
-233
| -27% | -$451 | ﹤0.01% | 5107 |
|
|
2023
Q2 | $2.18K | Sell |
876
-779
| -47% | -$2.13K | ﹤0.01% | 5279 |
|
|
2023
Q1 | $4.43K | Sell |
1,655
-22,749
| -93% | -$109K | ﹤0.01% | 4972 |
|
|
2022
Q4 | $133K | Sell |
24,404
-102,905
| -81% | -$862K | ﹤0.01% | 3910 |
|
|
2022
Q3 | $1.59M | Buy |
127,309
+126,097
| +10,404% | +$1.44M | ﹤0.01% | 2326 |
|
|
2022
Q2 | $6K | Sell |
1,212
-40,842
| -97% | -$226K | ﹤0.01% | 5576 |
|
|
2022
Q1 | $320K | Sell |
42,054
-225,119
| -84% | -$2.13M | ﹤0.01% | 3803 |
|
|
2021
Q4 | $2.73M | Buy |
267,173
+129,616
| +94% | +$1.65M | ﹤0.01% | 2357 |
|
|
2021
Q3 | $1.85M | Sell |
137,557
-48,244
| -26% | -$786K | ﹤0.01% | 2608 |
|
|
2021
Q2 | $4.08M | Buy |
185,801
+9,336
| +5% | +$207K | ﹤0.01% | 2075 |
|
|
2021
Q1 | $4.25M | Buy |
176,465
+168,304
| +2,062% | +$3.91M | ﹤0.01% | 1896 |
|
|
2020
Q4 | $147K | Buy |
8,161
+4,918
| +152% | +$73.5K | ﹤0.01% | 5227 |
|
|
2020
Q3 | $37K | Sell |
3,243
-20,555
| -86% | -$339K | ﹤0.01% | 5788 |
|
|
2020
Q2 | $577K | Sell |
23,798
-4,337
| -15% | -$71.7K | ﹤0.01% | 4107 |
|
|
2020
Q1 | $310K | Buy |
28,135
+15,835
| +129% | +$296K | ﹤0.01% | 4328 |
|
|
2019
Q4 | $325K | Sell |
12,300
-14,897
| -55% | -$348K | ﹤0.01% | 4789 |
|
|
2019
Q3 | $620K | Buy |
27,197
+12,221
| +82% | +$385K | ﹤0.01% | 4142 |
|
|
2019
Q2 | $459K | Buy |
14,976
+770
| +5% | +$16.2K | ﹤0.01% | 4512 |
|
|
2019
Q1 | $236K | Sell |
14,206
-98,379
| -87% | -$1.87M | ﹤0.01% | 4940 |
|
|
2018
Q4 | $2.16M | Buy |
112,585
+77,821
| +224% | +$2.91M | ﹤0.01% | 2593 |
|
|
2018
Q3 | $1.82M | Buy |
34,764
+12,463
| +56% | +$680K | ﹤0.01% | 2837 |
|
|
2018
Q2 | $969K | Buy |
22,301
+20,318
| +1,025% | +$871K | ﹤0.01% | 3394 |
|
|
2018
Q1 | $74K | Buy |
1,983
+120
| +6% | +$3.2K | ﹤0.01% | 5877 |
|
|
2017
Q4 | $36K | Buy |
+1,863
| New | +$40.1K | ﹤0.01% | 6400 |
|
Citigroup's GTHX Position: Q3 2024 in Review
Citigroup sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 10,736 shares — an estimated $24.5K sold.
Citigroup first reported a position in GTHX in Q4 2017 and held it in 27 quarters. The position peaked at $4.25M in Q1 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Citigroup reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Citigroup sold 10,736 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $24.5K.
- Citigroup first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2017 and held it in 27 quarters.
- Citigroup's G1 Therapeutics, Inc. Common Stock position peaked at $4.25M in Q1 2021.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Citigroup's 13F filing for Q3 2024, filed 12 Nov 2024.